Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Ocumension Signs $13.5 Million Deal for China Rights to Nicox Anti-Inflammatory Eye Drug

publication date: Jul 3, 2019

Ocumension, a Hong Kong ophthalmology company, acquired greater China rights to a treatment for acute blepharitis from France's Nicox in a $13.5 million agreement. Blepharitis is characterized by inflammation of the eyelid. NCX 4251, the third product that Ocumension has in-licensed from Nicox, is currently in a US Phase II trial. Previously, Ocumension acquired China rights to NCX 470 for glaucoma and ZerviateTM for allergic conjunctivitis. Ocumension is wholly owned by 6 Dimensions Capital, an investment firm formed by the merger of Wuxi Healthcare Ventures and Frontline BioVentures. More details....

Stock Symbol: (Paris: FR0013018124)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.